Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension

被引：0
|
作者：
Annette S Droste
David Rohde
Mirko Voelkers
Arthur Filusch
Thomas Bruckner
Mathias M Borst
Hugo A Katus
F Joachim Meyer
机构：
[1] Angiology and Respiratory Medicine,Department of Cardiology
[2] Institute for Medical Biometry and Informatics of the University,undefined
来源：
Respiratory Research | / 10卷
关键词：
Bosentan; Systolic Pulmonary Artery Pressure; Idiopathic Pulmonary Arterial Hypertension; Pulmonary Hemodynamic; Expiratory Airflow;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
    Droste, Annette S.
    Rohde, David
    Voelkers, Mirko
    Filusch, Arthur
    Bruckner, Thomas
    Borst, Mathias M.
    Katus, Hugo A.
    Meyer, F. Joachim
    [J]. RESPIRATORY RESEARCH, 2009, 10
  • [2] Ambrisentan -: Treatment of pulmonary arterial hypertension endothelin ETA receptor antagonist
    Sorbera, LA
    Castañer, J
    [J]. DRUGS OF THE FUTURE, 2005, 30 (08) : 765 - 770
  • [3] Treatment of pulmonary arterial hypertension with macitentan, dual endothelin receptor antagonist
    Bichara, Valentina M.
    Bevacqua, Raul J.
    [J]. INSUFICIENCIA CARDIACA, 2019, 14 (03) : 119 - 128
  • [4] Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension
    O'Callaghan, DS
    Gaine, SP
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (04) : 475 - 481
  • [5] Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
    Steiner, M. Kathryn
    Preston, Ioana R.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (05) : 943 - 952
  • [6] Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist for the treatment of pulmonary arterial hypertension
    Kingman, Martha
    Ruggiero, Rosechelle
    Torres, Fernando
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (11) : 1847 - 1858
  • [7] Influence Of Endothelin Receptor Antagonist For The Development Of Thyroid Dysfunction In Patients With Childhood-Onset Pulmonary Arterial Hypertension
    Nakayama, T.
    Takatsuki, S.
    Satoh, M.
    Aso, K.
    Ikehara, S.
    Matsuura, H.
    Saji, T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [8] Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension
    Barst, Robyn J.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (01) : 95 - 109
  • [9] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    Barst, Robyn J.
    Langleben, David
    Badesch, David
    Frost, Adaani
    Lawrence, E. Clinton
    Shapiro, Shelley
    Naeije, Robert
    Galie, Nazzareno
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 2049 - 2056
  • [10] The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension
    Avdeev, S. N.
    [J]. TERAPEVTICHESKII ARKHIV, 2016, 88 (07): : 89 - 97
12345